AOUMEYi003-A

The cell line is not validated yet.

General

Cell Line

hPSCreg name AOUMEYi003-A
Cite as:
AOUMEYi003-A
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 7th April 2025
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Meyer Children's Hospital IRCCS (AOUMEY)
Owner Meyer Children's Hospital IRCCS (AOUMEY)
Distributors
Derivation country Italy

General Information

* Is the cell line readily obtainable for third parties?
Yes
Cell line can only be used in: Lysosomal diseases

Donor Information

General Donor Information

Sex male
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Synonyms
  • Morquio Syndrome
  • Mucopolysaccharidosis IV
  • Mucopolysaccharidosis Type IV

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
Karyotyping method: hiPSC Genetic Analysis Kit

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA117982439

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Confirm that consent was obtained by a qualified professional Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Pediatric Ethics Committee of the Tuscany Region, Italy
Approval number No 58/2024
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
Any skin fibroblast that is part of some dermis.

Reprogramming method

Vector type Non-integrating
Vector Non-integrating, self-replicating RNA vector
Is reprogramming vector detectable?
No

Vector free reprogramming

Type of used vector free reprogramming factor(s)
Small molecules

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions

Surface coating Vitronectin
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
Medium mTeSR™ Plus
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
NANOG
Yes
SOX2
Yes
POU5F1 (OCT-4)
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
SRY-box transcription factor 17
Yes
GATA binding protein 4
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
T-box transcription factor T
Unknown
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
SRY-box transcription factor 1
Unknown

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XY
Karyotyping method: hiPSC Genetic Analysis Kit

Other Genotyping (Cell Line)